ARCHIVES

DCT Board Okays Contract Recompetitions, But Litton Bionetics May Be Barred From Two Supporting Gall’s Lab, Plus FCRF Program

This article is from The Cancer Letter archive.

Vol. 11 No. 41 | October 25, 1985

Download PDF Visit The Full Archive

Related Articles

Owens Becomes President, NCCR

June 21, 1996

Drug Approvals; Zykadia Granted Accelerated Approval For ALK+ NSCLC; ADXS-HPV Grated Orphan Drug Designation

May 9, 2014

In Brief: House Appropriations Subcommitee Plans Hearing On NCI March 24; New DTP Director Sought

February 25, 1983

Scientists should lobby Congress to support the project, Broad Institute Director Eric Lander says.

March 18, 2005

Report Urges Stronger NCI Nutritional research

December 10, 1999

Ethics Commission To Continue Consideration Of Compensation For Injured Research Subjects

June 20, 1980